DK1053313T3 - Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser - Google Patents

Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser

Info

Publication number
DK1053313T3
DK1053313T3 DK99903559T DK99903559T DK1053313T3 DK 1053313 T3 DK1053313 T3 DK 1053313T3 DK 99903559 T DK99903559 T DK 99903559T DK 99903559 T DK99903559 T DK 99903559T DK 1053313 T3 DK1053313 T3 DK 1053313T3
Authority
DK
Denmark
Prior art keywords
antisense oligonucleotides
dna methyltransferase
oligonucleotides complementary
optimized antisense
methyltransferase sequences
Prior art date
Application number
DK99903559T
Other languages
English (en)
Inventor
Robert A Macleod
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Application granted granted Critical
Publication of DK1053313T3 publication Critical patent/DK1053313T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DK99903559T 1998-02-03 1999-02-03 Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser DK1053313T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/018,034 US6066625A (en) 1998-02-03 1998-02-03 Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences

Publications (1)

Publication Number Publication Date
DK1053313T3 true DK1053313T3 (da) 2006-08-28

Family

ID=21785911

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99903559T DK1053313T3 (da) 1998-02-03 1999-02-03 Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser

Country Status (11)

Country Link
US (2) US6066625A (da)
EP (1) EP1053313B1 (da)
JP (1) JP3766592B2 (da)
AT (1) ATE324440T1 (da)
AU (1) AU758835B2 (da)
CA (1) CA2319086A1 (da)
DE (1) DE69931029T2 (da)
DK (1) DK1053313T3 (da)
ES (1) ES2263267T3 (da)
PT (1) PT1053313E (da)
WO (1) WO1999040186A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
WO2001085996A1 (en) * 2000-05-09 2001-11-15 Isis Pharmaceuticals, Inc. Methods of obtaining active antisense compounds
US20030083292A1 (en) * 2001-05-11 2003-05-01 Macleod Alan Robert Inhibitors of DNA methyltransferase isoforms
EP2505591A1 (en) 2005-02-11 2012-10-03 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting a drug resistant EGFR mutant
WO2006107751A2 (en) * 2005-04-01 2006-10-12 Methylgene, Inc. Combined therapy utilizing reduction of dna methyltansferase expression and/or activity and interferon
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
CA2617611A1 (en) * 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
AR060061A1 (es) * 2006-03-22 2008-05-21 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
WO2008046216A1 (en) * 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
ES2599458T3 (es) 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
GB201001088D0 (en) 2010-01-23 2010-03-10 Trillion Genomics Ltd Detection
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
GB201206209D0 (en) 2012-04-06 2012-05-23 Univ Leuven Kath Marker gene based diagnosis, staging and prognosis of prostate caner
JP6342392B2 (ja) 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
MX2015010700A (es) 2013-02-21 2017-01-23 Calitor Sciences Llc Compuestos heteroaromaticos como moduladores de la p13 cinasa.
US20160032316A1 (en) * 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
EP3124609A1 (en) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides
ES2781459T3 (es) 2015-07-29 2020-09-02 Ifom Fondazione St Firc Di Oncologia Molecolare Oligonucleótidos terapéuticos
US10308658B2 (en) 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
WO2018185341A1 (en) 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
KR102412183B1 (ko) * 2017-04-17 2022-06-23 주식회사 씨젠 올리고뉴클레오타이드 최적 조합의 제공방법
WO2023081927A2 (en) * 2021-11-08 2023-05-11 The General Hospital Corporation Treating chemoresistant forms of leukemia and other cancers that overexpress rna binding protein fxr1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030557A (en) * 1987-11-24 1991-07-09 Ml Technology Venture Means and method for enhancing nucleic acid hybridization
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides

Also Published As

Publication number Publication date
US6506735B1 (en) 2003-01-14
AU2405999A (en) 1999-08-23
WO1999040186A1 (en) 1999-08-12
DE69931029D1 (de) 2006-06-01
US6066625A (en) 2000-05-23
ATE324440T1 (de) 2006-05-15
EP1053313A1 (en) 2000-11-22
PT1053313E (pt) 2006-06-30
JP2002502602A (ja) 2002-01-29
JP3766592B2 (ja) 2006-04-12
CA2319086A1 (en) 1999-08-12
AU758835B2 (en) 2003-04-03
EP1053313B1 (en) 2006-04-26
ES2263267T3 (es) 2006-12-01
DE69931029T2 (de) 2006-11-23

Similar Documents

Publication Publication Date Title
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
WO1999010486A3 (en) Mdm2-specific antisense oligonucleotides
DK0731835T3 (da) Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
WO2002052031A3 (en) Nucleic acid amplification
BR0308424A (pt) Métodos e meios para infra-regular eficientemente a expressão de qualquer gene de interesse em células e organismos eucarióticos
ATE280772T1 (de) Antisense oligonukleotidmodulation der raf genexpression
EP0788307A4 (en) MODULATION BY OLIGONUCLEOTIDES OF THE PROTEIN ASSOCIATED WITH MULTIPLE ANTI-CANCER RESISTANCE
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
EP1250157A4 (en) ANTISENS MODULATION OF THE EXPRESSION OF THE INDUCIBLE NITROGEN MONOXIDE SYNTHASE
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
WO2003046132A3 (en) Antisense modulation of myd88 expression
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO1999046374A3 (de) Menschliche nukleinsäuresequenzen aus prostatatumorgewebe
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
EP1248633A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF GLYCOGEN SYNTHASE KINASE 3 BETA
EP1322658A4 (en) OLIGONUCLEOTIDE MODULATION OF HER-1 RECEPTOR EXPRESSION
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2004085681A3 (en) Global linear non-biased nucleic acid amplification
WO1999046375A3 (de) Menschliche nukleinsäuresequenzen aus prostatagewebe